Search Results - "BODDY, Alan V"

Curcumin as a clinically-promising anti-cancer agent: pharmacokinetics and drug interactions by Adiwidjaja, Jeffry, McLachlan, Andrew J, Boddy, Alan V

“…Curcumin has been extensively studied for its anti-cancer properties. While a diverse array of in vitro and preclinical research support the prospect of…”
Get more information

Implementation of a Physiologically Based Pharmacokinetic Modeling Approach to Guide Optimal Dosing Regimens for Imatinib and Potential Drug Interactions in Paediatrics by Adiwidjaja, Jeffry, Boddy, Alan V, McLachlan, Andrew J

“…Long-term use of imatinib is effective and well-tolerated in children with chronic myeloid leukaemia (CML) yet defining an optimal dosing regimen for imatinib…”
Get full text

An LC/MS/MS method for stable isotope dilution studies of β-carotene bioavailability, bioconversion, and vitamin A status in humans[S] by Oxley, Anthony, Berry, Philip, Taylor, Gordon A., Cowell, Joseph, Hall, Michael J., Hesketh, John, Lietz, Georg, Boddy, Alan V.

“…Isotope dilution is currently the most accurate technique in humans to determine vitamin A status and bioavailability/bioconversion of provitamin A carotenoids…”
Get full text

Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors by PLUMMER, Ruth, VIDAL, Laura, REID, Gregory K, MCLEOD, A. Robert, BESTERMAN, Jeffrey M, LEE, Chooi, JUDSON, Ian, CALVERT, Hilary, BODDY, Alan V, GRIFFIN, Melanie, LESLEY, Mark, DE BONO, Johann, COULTHARD, Sally, SLUDDEN, Julieann, SIU, Lillian L, CHEN, Eric X, OZA, Amit M

“…Purpose: To assess the safety and tolerability, pharmacokinetics, and early evidence of antitumor activity of escalating doses of MG98, an antisense…”
Get full text

Inhibition of Poly(ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma by DANIEL, Rachel A, ROZANSKA, Agata L, CURTIN, Nicola J, CLIFFORD, Steven C, THOMAS, Huw D, MULLIGAN, Evan A, DREW, Yvette, CASTELBUONO, Deborah J, HOSTOMSKY, Zdenek, PLUMMER, E. Ruth, BODDY, Alan V, TWEDDLE, Deborah A

“…Purpose: High-risk neuroblastoma is characterized by poor survival rates, and the development of improved therapeutic approaches is a priority. Temozolomide…”
Get full text

Is there scope for better individualisation of anthracycline cancer chemotherapy? by Sallustio, Benedetta C., Boddy, Alan V.

“…Anthracyclines are used to treat solid and haematological cancers, particularly breast cancers, lymphomas and childhood cancers. Myelosuppression and…”
Get full text

A Phase I and Pharmacokinetic Study of Paclitaxel Poliglumex (XYOTAX), Investigating Both 3-Weekly and 2-Weekly Schedules by BODDY, Alan V, PLUMMER, E. Ruth, CALVERT, A. Hilary, TODD, Radha, SLUDDEN, Julieann, GRIFFIN, Melanie, ROBSON, Lesley, CASSIDY, James, BISSETT, Donald, BERNAREGGI, Alberto, VERRILL, Mark W

“…Purpose: To determine the safety, maximum tolerated dose, pharmacokinetics, and toxicities associated with administration of paclitaxel poliglumex (PPX,…”
Get full text

Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy by Jamieson, David, Cresti, Nicola, Bray, Johanne, Sludden, Julieann, Griffin, Melanie J, Hawsawi, Nahed M, Famie, Eve, Mould, Emily V.A, Verrill, Mark W, May, Felicity E.B, Boddy, Alan V

“…OBJECTIVEA SNP in the NQO1 gene has been implicated in the response of patients with breast cancer to anthracycline containing regimens. NQO1, and its…”
Get full text

Phase I Clinical and Pharmacokinetic Study of Pemetrexed and Carboplatin in Patients With Malignant Pleural Mesothelioma by HUGHES, Andy, CALVERT, Paula, CALVERT, Hilary, AZZABI, Ashraf, PLUMMER, Ruth, JOHNSON, Rob, RUSTHOVEN, Jim, GRIFFIN, Melanie, FISHWICK, Kevin, BODDY, Alan V, VERRILL, Mark

“…To determine the maximum tolerated dose (MTD) of pemetrexed and carboplatin given in combination, to derive a recommended dose for phase II studies, and to…”
Get full text

Physiologically-Based Pharmacokinetic Predictions of the Effect of Curcumin on Metabolism of Imatinib and Bosutinib: In Vitro and In Vivo Disconnect by Adiwidjaja, Jeffry, Boddy, Alan V, McLachlan, Andrew J

“…Purpose This study aimed to investigate the potential pharmacokinetic interactions between curcumin, imatinib and bosutinib, combining In Vitro and in silico…”
Get full text

Potential for pharmacokinetic interactions between Schisandra sphenanthera and bosutinib, but not imatinib: in vitro metabolism study combined with a physiologically‐based pharmacokinetic modelling approach by Adiwidjaja, Jeffry, Boddy, Alan V., McLachlan, Andrew J.

“…Aims This study aimed to investigate the potential interaction between Schisandra sphenanthera, imatinib and bosutinib combining in vitro and in silico…”
Get full text

Interactions between natural products and cancer treatments: underlying mechanisms and clinical importance by Chan, Wai-Jo Jocelin, Adiwidjaja, Jeffry, McLachlan, Andrew J., Boddy, Alan V., Harnett, Joanna E.

“…Natural products, also referred to as dietary supplements, complementary and alternative medicines, and health or food supplements are widely used by people…”
Get full text

Physiologically Based Pharmacokinetic Modelling of Hyperforin to Predict Drug Interactions with St John’s Wort by Adiwidjaja, Jeffry, Boddy, Alan V., McLachlan, Andrew J.

“…Background and Objectives Herb–drug interactions with St John’s wort (SJW) have been widely studied in numerous clinical studies. The objective of this study…”
Get full text

Physiologically‐based pharmacokinetic model predictions of inter‐ethnic differences in imatinib pharmacokinetics and dosing regimens by Adiwidjaja, Jeffry, Gross, Annette S., Boddy, Alan V., McLachlan, Andrew J.

“…Aims This study implements a physiologically‐based pharmacokinetic (PBPK) modelling approach to investigate inter‐ethnic differences in imatinib…”
Get full text

Physiologically based pharmacokinetic model predictions of natural product-drug interactions between goldenseal, berberine, imatinib and bosutinib by Adiwidjaja, Jeffry, Boddy, Alan V., McLachlan, Andrew J.

“…Purpose This study implements a physiologically based pharmacokinetic (PBPK) modelling approach to predict the effect of hydrastine and berberine, two major…”
Get full text

NAD(P)H:Quinone Oxidoreductase 1 and NRH:Quinone Oxidoreductase 2 Activity and Expression in Bladder and Ovarian Cancer and Lower NRH:Quinone Oxidoreductase 2 Activity Associated with an NQO2 Exon 3 Single-Nucleotide Polymorphism by JAMIESON, David, WILSON, Kerrie, PRIDGEON, Simon, MARGETTS, Jane P, EDMONDSON, Richard J, LEUNG, Hing Y, KNOX, Richard, BODDY, Alan V

“…Purpose: NRH:quinone oxidoreductase 2 (NQO2) is a homologue of NAD(P)H:quinone oxidoreductase 1 (NQO1). Despite 54% homology with human NQO1, NQO2 has little…”
Get full text

Imagestream detection and characterisation of circulating tumour cells – A liquid biopsy for hepatocellular carcinoma? by Ogle, Laura F, Orr, James G, Willoughby, Catherine E, Hutton, Claire, McPherson, Stuart, Plummer, Ruth, Boddy, Alan V, Curtin, Nicola J, Jamieson, David, Reeves, Helen L

“…Graphical abstract…”
Get full text

A Retinol Isotope Dilution Equation Predicts Both Group and Individual Total Body Vitamin A Stores in Adults Based on Data from an Early Postdosing Blood Sample by Green, Michael H, Ford, Jennifer Lynn, Green, Joanne Balmer, Berry, Philip, Boddy, Alan V, Oxley, Anthony, Lietz, Georg

“…Retinol isotope dilution (RID) is used to determine vitamin A total body stores (TBS) after an oral dose of a vitamin A stable isotope. The generally accepted…”
Get more information

Physiologically Based Pharmacokinetic Modeling Approaches for Patients With SARS‐CoV‐2 Infection: A Case Study With Imatinib by Adiwidjaja, Jeffry, Adattini, Josephine A., Boddy, Alan V., McLachlan, Andrew J.

“…Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection, which causes coronavirus disease 2019 (COVID‐19), manifests as mild respiratory…”
Get full text

Pharmacokinetic Investigation of Imatinib Using Accelerator Mass Spectrometry in Patients with Chronic Myeloid Leukemia by Boddy, Alan V, Sludden, Julieann, Griffin, Melanie J, Garner, Colin, Kendrick, John, Mistry, Pritesh, Dutreix, Catherine, Newell, David R, O'Brien, Stephen G

“…Purpose: To investigate the potential use of accelerator mass spectrometry (AMS) in the study of the clinical pharmacology of imatinib. Experimental Design:…”
Get full text